Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. (Q51355802)

From Wikidata

Jump to navigation Jump to search

scientific article published on 9 June 2012

Language	Label	Description	Also known as
English	Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.	scientific article published on 9 June 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22683131

Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22683131

type 2 diabetes

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

insulin glargine

1 reference

based on heuristic

inferred from title

Juliana Chung-ngor Chan

2

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22683131

author name string

Pablo Aschner

1

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22683131

David R Owens

3

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22683131

Sylvie Picard

4

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22683131

Edward Wang

5

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22683131

Marie-Paule Dain

6

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22683131

Valérie Pilorget

7

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22683131

Akram Echtay

8

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22683131

Vivian Fonseca

9

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22683131

EASIE investigators

10

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22683131

language of work or name

0 references

publication date

9 June 2012

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22683131

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22683131

379

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22683131

9833

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22683131

2262-2269

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22683131

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive glucose control and macrovascular outcomes in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Improvement of cardiovascular risk factors in patients with type 2 diabetes after long-term continuous subcutaneous insulin infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Hypoglycemia, diabetes, and cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960439-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(12)60439-5

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22683131

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22683131

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51355802&oldid=1563401032"